A new two-drug monthly regimen for the treatment of HIV-1 infected adults has generated positive data in a pivotal Phase 3 study, ViiV Healthcare Ltd announced on 15 August.
The study, ATLAS, met its primary endpoint showing similar efficacy for the once-a-month injectable two-drug treatment compared with a standard of care, daily, oral three-drug regimen.